News articles about CTI BioPharma (NASDAQ:CTIC) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CTI BioPharma earned a news impact score of 0.23 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.3725910200186 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern’s analysis:
- CTI BIOPHARMA CORP : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- BRIEF-CTI Biopharma Corp Says Co Entered Into A Loan And Security Agreement (CTIC) (uk.news.yahoo.com)
- CTI BIOPHARMA CORP. (NASDAQ:CTIC) Files An 8-K Entry into a Material Definitive Agreement (4-traders.com)
- 35 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga (benzinga.com)
CTI BioPharma (NASDAQ CTIC) opened at $2.73 on Tuesday. The company has a current ratio of 2.19, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26. CTI BioPharma has a 1-year low of $2.63 and a 1-year high of $6.48.
CTIC has been the topic of several recent research reports. ValuEngine lowered shares of CTI BioPharma from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th. Jefferies Group initiated coverage on shares of CTI BioPharma in a report on Tuesday, September 12th. They set a “buy” rating and a $7.50 target price on the stock.
In related news, Director Richard L. Love sold 14,600 shares of CTI BioPharma stock in a transaction on Friday, September 29th. The shares were sold at an average price of $3.21, for a total transaction of $46,866.00. Following the transaction, the director now owns 84,318 shares in the company, valued at approximately $270,660.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.08% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/05/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-cti-biopharma-ctic-stock-price.html.
About CTI BioPharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
What are top analysts saying about CTI BioPharma Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CTI BioPharma Corp. and related companies.